Skip to content

Aurinia Pharmaceuticals AUPH Cost not yet recognized

Cost not yet recognized at other companies

L3Harris Technologies logo
L3Harris TechnologiesLHX
$20M0.0%
Ametek logo
AmetekAME
$21.9M-7.2%
Service Corporation International logo
Service Corporation InternationalSCI
$6.6M-5.7%
Perimeter Solutions logo
Perimeter SolutionsPRM
$46.1M+52.6%
Balchem logo
BalchemBCPC
$35.8M+13.9%
UiPath logo
UiPathPATH
$59.8M-30.4%

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.39B+78.5%

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Reported directly by Aurinia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's cost not yet recognized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's cost not yet recognized?
Aurinia Pharmaceuticals (AUPH) reported cost not yet recognized of $15.3M in Q1 2026.
How has Aurinia Pharmaceuticals's cost not yet recognized changed year-over-year?
Aurinia Pharmaceuticals's cost not yet recognized decreased by 41.2% year-over-year, from $26M to $15.3M.